References

I-40

1. Micromedex DrugDex Compendium®. 2024. Pertuzumab.

2. Clinical Pharmacology™Compendium 2024. Tampa FL: Gold Standard, Inc. Pertuzumab.

3. Perjeta (pertuzumab) injection, for intravenous use [package insert]. Genentech, Inc. South San Francisco, CA. Revised. 02/2021.

4. Urruticoechea A, Rizwanullah M, Im S, et al. Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy. *J Clin Oncol.*2017;35:3030-3038.

5. National Comprehensive Cancer Network (NCCN). Pertuzumab. NCCN Drugs and Biologics Compendium®. 2024.

6. Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2- amplified metastatic colorectal cancer: An updated report from a multicenter, open-label, phase 2a, multiple basket study. *The Lancet.*2019;20(4):518-530.

7. Wang R, Smyth LM, Iyengar N, et al. Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with human epidermal growth receptor 2 overexpressing metastatic breast cancer: 5-year follow- *Oncologist*. 2019;24(8):646-652.

8. Kurzock R, Bowles DW, Kang H, Meric-Bernstam F, et al.Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: Results from My Pathway, a phase IIa multiple basket study. *Ann Oncol.*2020;31:412-421.

9. Pertuzumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated 02/09/2021.